Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
2018 · The Lancet · 5,257 citations
https://doi.org/10.1016/s0140-6736(18)30207-1
G
Guohong Han
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
289
Papers
19.0K
Citations
54
h-index
125
i10-index
Guohong Han is an academic researcher from Northwest University. The author has contributed to research in topics: Liver Disease and Transplantation & Liver Disease Diagnosis and Treatment & Hepatocellular Carcinoma Treatment and Prognosis. The author has an h-index of 54, co-authored 246 publications.
ORCID: 0000-0003-4568-3776Papers by this author
worksRegorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
2016 · The Lancet · 3,590 citations
https://doi.org/10.1016/s0140-6736(16)32453-9
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
2020 · Liver Cancer · 813 citations
https://doi.org/10.1159/000509424
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
2023 · Liver Cancer · 404 citations
https://doi.org/10.1159/000530495
Hepatic Hydrothorax
2017 · Annals of Hepatology · 60 citations
https://doi.org/10.5604/01.3001.0010.7533
The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization
2016 · Scientific Reports · 43 citations
https://doi.org/10.1038/srep19851
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat